News and Trends 18 Apr 2017 Circassia Freezes its Allergy Portfolio after a Second Failed Clinical Trial Circassia Pharmaceuticals will stop investing in its allergy programs due to two failed clinical trials in which the placebo beat its allergy immunotherapy. Circassia Pharmaceuticals has released the results from a Phase IIb trial for a house dust mite allergy immunotherapy. Although the treatment greatly reduced allergy symptoms in the patients, so did the placebo, making […] April 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 18 Apr 2017 The Top 12 Biotech Leaders You Should Know in Basel After exploring Munich and the Golden Triangle, we head to another biotech hotspot full of people that should be on your list of who’s who. Basel is home to some really big biotech and pharma companies and it’s consequently a cornerstone of the excellence Switzerland has demonstrated in the industry (also seen in Zurich). As a key […] April 18, 2017 - 6 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 18 Apr 2017 Patent Eligibility: How to Tell if your Life Science Invention is Patentable So you have an invention, but can you protect it with a patent? This primer will teach you about the criteria, from non-obviousness to inventiveness. How do we define “patent eligibility“? Broadly, the term means that an invention falls within a category of inventions for which the patent laws provide patent protection in general. Inventions […] April 18, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 17 Apr 2017 Meet One of the Most Successful German Biotech Leaders Ever Patrick Baeuerle is the German biotech leader I wanted to interview the most (besides Simon Moroney from MorphoSys, who came to our Meetup in Munich last week). Patrick has explored and succeeded in just about every area of life sciences, be it as a highly cited academic researcher, a professor at Freiburg University, head of drug […] April 17, 2017 - 6 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
Inside Labiotech 14 Apr 2017 Why is Ingmar Hoerr, Co-Founder & CEO of CureVac, reading Labiotech.eu? Leaders & Readers: I had a chat with Ingmar Hoerr about why he reads Labiotech.eu. He is the co-founder and CEO of CureVac, one of the most successful European biotechs. This interview has just been lightly edited for grammar. Why do you read Labiotech.eu, and how does it help you in your job? I really like the […] April 14, 2017 - 2 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
Startup Scout 14 Apr 2017 This Norwegian Biotech Aims to Unlock the Full Potential of Cancer Drugs This week we visited the Norwegian PCI Biotech. Based in Oslo, this company has developed a light-sensitive technology, which allows to activate cancer drugs at specific sites of the body by targeted illumination. Mission: PCI Biotech focuses on the development of new therapies for the treatment of cancer based on its photochemical internalisation (PCI) technology. The PCI technology consists of a photosensitising […] April 14, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2017 Next-Gen Cancer Antibody Technology from Germany enters the Clinic Apogenix’ partner AbbVie has started the first clinical trial for an immuno-oncology candidate with the potential to outperform antibody therapy. The German biotech Apogenix has announced that its partner AbbVie has initiated a Phase I trial testing its next-generation immuno-oncology technology in patients suffering from solid tumors, non-Hodgkin’s lymphoma (NHL) and acute myeloid leukemia (AML). The candidate […] April 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2017 French Oncolytic Virus Vaccine for Breast Cancer enters Phase II After positive results in Phase I, Transgene has started Phase II with Pexa-Vec in combination with chemotherapy to treat breast cancer and sarcoma. After years of financial instability, Transgene is stepping up its game in cancer immunotherapies. Last year, its first Phase III trial and a deal with Merck and Pfizer brought the hopes of investors […] April 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2017 Belgian Research takes first steps to make Biofuel out of Grass Researchers from the University of Ghent are using bacteria to turn grass into chemicals for bioplastics and biofuel. Could this process be scaled up to fuel planes? A grass bioconversion project is being developed at the Centre for Microbial Ecology and Technology (CMET) of the University of Ghent, and it has recently taken an important step forward. […] April 13, 2017 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2017 Coming from Behind: How Italy is Revamping its Biotech Industry Italy’s biotech industry lags behind in Europe, but the situation is starting to change with coordinated efforts in research, finance and organization. While ‘European biotech’ brings to mind France, Germany and the UK, Italy is cultivating its own thriving ecosystem. It claims internationally renowned scientific research institutions, including the University of Perugia and the San Raffaele […] April 13, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 12 Apr 2017 Swiss Pharma Clears €37M Funding to Develop a New Class of Antibiotics Swiss Polyphor has closed a €37M (CHF40M) private funding round to finance the development of its most advanced candidate tackling antibiotic resistances. Polyphor is a clinical stage pharma developing a specific class of so called ‘macrocyclic drugs‘, which are chemically defined by a ring structure. The company’s pipeline is covering a broad range of diseases such as […] April 12, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Interview 12 Apr 2017 Video Interview: How Morphosys Grew Into a Billion-Euro Biotech At our first, but for sure not last meetup in Munich last Monday, Philip had the pleasure to have a chat with Simon Moroney, CEO and co-founder of the biggest biotech in Germany, Morphosys. Their topics ranged from Morphosys’ current pipeline and previous failures to the immuno-oncology hype and company culture. Morphosys started out with its […] April 12, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email